| Title |
Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?
|
|---|---|
| Published in |
OncoTargets and therapy, June 2013
|
| DOI | 10.2147/ott.s46883 |
| Pubmed ID | |
| Authors |
Tracey Hurrell, Kim Outhoff |
| Abstract |
Despite trastuzumab having enhanced selectivity for human epidermal growth factor receptor 2 (HER-2) overexpressing breast cancer cells, treatment is hampered by interindividual variation and tumors with high mitogenic potential. The lack of significant clinical benefit in certain patient cohorts suggests that HER-2 expression is ineffective as a sole prognostic indicator of response to therapy. Therefore, optimizing the clinical role of trastuzumab in drug combinations remains critical for clinical success. |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 21% |
| Student > Ph. D. Student | 5 | 21% |
| Student > Master | 4 | 17% |
| Other | 2 | 8% |
| Student > Doctoral Student | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 33% |
| Agricultural and Biological Sciences | 5 | 21% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Psychology | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Other | 0 | 0% |
| Unknown | 5 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2013.
All research outputs
#17,285,036
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#1,146
of 3,016 outputs
Outputs of similar age
#130,276
of 206,477 outputs
Outputs of similar age from OncoTargets and therapy
#24
of 45 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,477 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.